Three Questions for Biotech
When the market returns to steady-state, following its current valuation gyrations, we'd like to see biotechs answer three basic questions. Who will be the new financiers of the biotech industry--investors or pharma? How will biotechs show they can increase their market value at competitive rates off already high valuations? How will the biotech industry handle its public image--particularly as genomics becomes a consumer issue?
You may also be interested in...
The European Commission has updated its rolling plan. It now looks as if current member state rules for non-medical products could persist beyond the 26 May 2021 deadline.
GSK launches a 100% natural saline spray in the UK to compliment its Piri hayfever brand portfolio.
Progress for two US-based companies in the race to develop a COVID-19 vaccine.